

1 5 DEC 2006

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Patrick J. Halloran Aventis Pasteur, Inc. Intellectual Property, Knerr Bldg. One Discovery Drive Swiftwater, PA 18370

In re Application of

PARRINGTON, et al.

Application No.: 10/510,677

PCT No.: PCT/US03/10916

Int. Filing Date: 09 April 2003 Priority Date: 09 April 2002

Atty. Docket No.: API-01-20-US

MODIFIED CEA NUCLEIC ACID AND

EXPRESSION VECTORS

DECISION ON PETITION

UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 04 August 2006 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" and the prompt filing of the petition satisfies the requirement of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicant has now provided a diskette containing a computer readable form of the Sequence Listing free of any defects. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America. Further, a review of the application file reveals that all of the requirements of 35 U.S.C. 371 for entry into the national stage in the United States have been previously satisfied.

The application has an international filing date of 09 April 2003 under 35 U.S.C. 363 and will be given a date of **06 October 2004** under 35 U.S.C. 371(c)(1), (c)(2) and (c)(4).

This application is being returned to the United States Designated/Elected Office (DO/EO/US) for treatment in accordance with this decision.

Derek A. Putonen Attorney Advisor

Office of PCT Legal Administration

Tel: (571) 272-3294 Fax: (571) 273-0459